{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:12:25Z","timestamp":1770819145504,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04469\/2020"],"award-info":[{"award-number":["UIDB\/04469\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04469\/2020"],"award-info":[{"award-number":["UIDB\/04469\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04469\/2020"],"award-info":[{"award-number":["UIDB\/04469\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04469\/2020"],"award-info":[{"award-number":["UIDB\/04469\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04469\/2020"],"award-info":[{"award-number":["UIDB\/04469\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04469\/2020"],"award-info":[{"award-number":["UIDB\/04469\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000004"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000004"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000004"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000004"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000004"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000004"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000004"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000004"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000004"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000004"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000004"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000004"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triple-negative breast cancer is the most aggressive subtype of invasive breast cancer with a poor prognosis and no approved targeted therapy. Hence, the identification of new and specific ligands is essential to develop novel targeted therapies. In this study, we aimed to identify new aptamers that bind to highly metastatic breast cancer MDA-MB-231 cells using the cell-SELEX technology aided by high throughput sequencing. After 8 cycles of selection, the aptamer pool was sequenced and the 25 most frequent sequences were aligned for homology within their variable core region, plotted according to their free energy and the key nucleotides possibly involved in the target binding site were analyzed. Two aptamer candidates, Apt1 and Apt2, binding specifically to the target cells with <jats:inline-formula><jats:alternatives><jats:tex-math>$$K_{d}$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                  <mml:msub>\n                    <mml:mi>K<\/mml:mi>\n                    <mml:mi>d<\/mml:mi>\n                  <\/mml:msub>\n                <\/mml:math><\/jats:alternatives><\/jats:inline-formula> values of 44.3\u2009\u00b1\u200913.3\u00a0nM and 17.7\u2009\u00b1\u20092.7\u00a0nM, respectively, were further validated. The binding analysis clearly showed their specificity to MDA-MB-231 cells and suggested the targeting of cell surface receptors. Additionally, Apt2 revealed no toxicity in vitro and showed potential translational application due to its affinity to breast cancer tissue sections. Overall, the results suggest that Apt2 is a promising candidate to be used in triple-negative breast cancer treatment and\/or diagnosis.<\/jats:p>","DOI":"10.1038\/s41598-021-87998-y","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T10:19:00Z","timestamp":1619000340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Selection of aptamers against triple negative breast cancer cells using high throughput sequencing"],"prefix":"10.1038","volume":"11","author":[{"given":"D\u00e9bora","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Joaquim","family":"Barbosa","sequence":"additional","affiliation":[]},{"given":"Diana A.","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"C\u00e1tia","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds D. R.","family":"Melo","sequence":"additional","affiliation":[]},{"given":"Meltem","family":"Avci-Adali","sequence":"additional","affiliation":[]},{"given":"Hans P.","family":"Wendel","sequence":"additional","affiliation":[]},{"given":"Ligia R.","family":"Rodrigues","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"87998_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"87998_CR2","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.2147\/OTT.S105716","volume":"9","author":"J-F Zhang","year":"2016","unstructured":"Zhang, J.-F., Liu, J., Wang, Y. & Zhang, B. Novel therapeutic strategies for patients with triple-negative breast cancer. Oncol. Targets Ther. 9, 6519\u20136528. https:\/\/doi.org\/10.2147\/OTT.S105716 (2016).","journal-title":"Oncol. Targets Ther."},{"key":"87998_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/696208","volume":"2011","author":"A Gucalp","year":"2011","unstructured":"Gucalp, A. & Traina, T. A. Triple-negative breast cancer: adjuvant therapeutic options. Chemother. Res. Pract. 2011, 1\u201313. https:\/\/doi.org\/10.1155\/2011\/696208 (2011).","journal-title":"Chemother. Res. Pract."},{"key":"87998_CR4","doi-asserted-by":"publisher","first-page":"1500053","DOI":"10.1002\/advs.201500053","volume":"2","author":"TFS Mendes","year":"2015","unstructured":"Mendes, T. F. S., Kluskens, L. D. & Rodrigues, L. R. Triple negative breast cancer: nanosolutions for a big challenge. Adv. Sci. 2, 1500053. https:\/\/doi.org\/10.1002\/advs.201500053 (2015).","journal-title":"Adv. Sci."},{"issue":"6","key":"87998_CR5","doi-asserted-by":"publisher","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","volume":"23","author":"F Andr\u00e9","year":"2012","unstructured":"Andr\u00e9, F. & Zielinski, C. C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann. Oncol. 23(6), vi46\u2013vi51 (2012).","journal-title":"Ann. Oncol."},{"key":"87998_CR6","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2217\/fon-2019-0059","volume":"15","author":"J Cort\u00e9s","year":"2019","unstructured":"Cort\u00e9s, J. et al. IMpassion132 phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Futur. Oncol. 15, 1951\u20131961. https:\/\/doi.org\/10.2217\/fon-2019-0059 (2019).","journal-title":"Futur. Oncol."},{"key":"87998_CR7","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/jcm9040940","volume":"9","author":"MY Keung","year":"2020","unstructured":"Keung, M. Y., Wu, Y., Badar, F. & Vadgama, J. V. Response of breast cancer cells to PARP inhibitors is independent of BRCA status. J. Clin. Med. 9, 940. https:\/\/doi.org\/10.3390\/jcm9040940 (2020).","journal-title":"J. Clin. Med."},{"key":"87998_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.18632\/oncoscience.474","volume":"6","author":"M Beniey","year":"2019","unstructured":"Beniey, M., Haque, T. & Hassan, S. Translating the role of PARP inhibitors in triple-negative breast cancer. Oncoscience 6, 287\u2013288. https:\/\/doi.org\/10.18632\/oncoscience.474 (2019).","journal-title":"Oncoscience"},{"key":"87998_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrd.2016.199","volume":"16","author":"J Zhou","year":"2017","unstructured":"Zhou, J. & Rossi, J. Aptamers as targeted therapeutics: current potential and challenges. Nat. Rev. Drug Discov. 16, 181\u2013202. https:\/\/doi.org\/10.1038\/nrd.2016.199 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"87998_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.bioeng.2007.06.001","volume":"24","author":"R Stoltenburg","year":"2007","unstructured":"Stoltenburg, R., Reinemann, C. & Strehlitz, B. SELEX\u2014a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol. Eng. 24, 381\u2013403. https:\/\/doi.org\/10.1016\/j.bioeng.2007.06.001 (2007).","journal-title":"Biomol. Eng."},{"key":"87998_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2020.113620","author":"Y Zhong","year":"2020","unstructured":"Zhong, Y., Zhao, J. & Chen, F. Advances of aptamers screened by Cell-SELEX in selection procedure, cancer diagnostics and therapeutics. Anal. Biochem. https:\/\/doi.org\/10.1016\/j.ab.2020.113620 (2020).","journal-title":"Anal. Biochem."},{"key":"87998_CR12","doi-asserted-by":"publisher","first-page":"16281","DOI":"10.3390\/s150716281","volume":"15","author":"T-H Ku","year":"2015","unstructured":"Ku, T.-H. et al. Nucleic acid aptamers: an emerging tool for biotechnology and biomedical sensing. Sensors 15, 16281\u201316313. https:\/\/doi.org\/10.3390\/s150716281 (2015).","journal-title":"Sensors"},{"key":"87998_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1126\/science.2200121","volume":"249","author":"C Tuerk","year":"1990","unstructured":"Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (80-) 249, 505\u2013510. https:\/\/doi.org\/10.1126\/science.2200121 (1990).","journal-title":"Science (80-)"},{"key":"87998_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/346818a0","volume":"346","author":"AD Ellington","year":"1990","unstructured":"Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818\u2013822. https:\/\/doi.org\/10.1038\/346818a0 (1990).","journal-title":"Nature"},{"key":"87998_CR15","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/nprot.2010.66","volume":"5","author":"K Sefah","year":"2010","unstructured":"Sefah, K., Shangguan, D., Xiong, X., O\u2019Donoghue, M. B. & Tan, W. Development of DNA aptamers using cell-SELEX. Nat. Protoc. 5, 1169\u20131185 (2010).","journal-title":"Nat. Protoc."},{"key":"87998_CR16","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1021\/ac501205q","volume":"86","author":"X Li","year":"2014","unstructured":"Li, X. et al. In vitro selection of DNA aptamers for metastatic breast cancer cell recognition and tissue imaging. Anal. Chem. 86, 6596\u20136603. https:\/\/doi.org\/10.1021\/ac501205q (2014).","journal-title":"Anal. Chem."},{"key":"87998_CR17","doi-asserted-by":"publisher","first-page":"8142","DOI":"10.1038\/s41598-019-44654-w","volume":"9","author":"K Pleiko","year":"2019","unstructured":"Pleiko, K. et al. Differential binding cell-SELEX method to identify cell-specific aptamers using high-throughput sequencing. Sci. Rep. 9, 8142. https:\/\/doi.org\/10.1038\/s41598-019-44654-w (2019).","journal-title":"Sci. Rep."},{"key":"87998_CR18","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1039\/C8BM00787J","volume":"6","author":"M Liu","year":"2018","unstructured":"Liu, M., Yang, T., Chen, Z., Wang, Z. & He, N. Differentiating breast cancer molecular subtypes using a DNA aptamer selected against MCF-7 cells. Biomater. Sci. 6, 3152\u20133159. https:\/\/doi.org\/10.1039\/C8BM00787J (2018).","journal-title":"Biomater. Sci."},{"key":"87998_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.omtn.2018.07.008","volume":"12","author":"W-M Li","year":"2018","unstructured":"Li, W.-M., Zhou, L.-L., Zheng, M. & Fang, J. Selection of metastatic breast cancer cell-specific aptamers for the capture of CTCs with a metastatic phenotype by cell-SELEX. Mol. Ther. Nucl. Acids 12, 707\u2013717. https:\/\/doi.org\/10.1016\/j.omtn.2018.07.008 (2018).","journal-title":"Mol. Ther. Nucl. Acids"},{"key":"87998_CR20","doi-asserted-by":"publisher","first-page":"8070","DOI":"10.1021\/acs.analchem.8b05941","volume":"91","author":"Q Wu","year":"2019","unstructured":"Wu, Q. et al. Evolution of nucleic acid aptamers capable of specifically targeting glioma stem cells via cell-SELEX. Anal. Chem. 91, 8070\u20138077. https:\/\/doi.org\/10.1021\/acs.analchem.8b05941 (2019).","journal-title":"Anal. Chem."},{"key":"87998_CR21","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1093\/nar\/gkv308","volume":"43","author":"J Hoinka","year":"2015","unstructured":"Hoinka, J. et al. Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery. Nucl. Acids Res. 43, 5699\u20135707. https:\/\/doi.org\/10.1093\/nar\/gkv308 (2015).","journal-title":"Nucl. Acids Res."},{"key":"87998_CR22","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1093\/nar\/gkv534","volume":"43","author":"A Levay","year":"2015","unstructured":"Levay, A. et al. Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment. Nucl. Acids Res. 43, e82\u2013e82. https:\/\/doi.org\/10.1093\/nar\/gkv534 (2015).","journal-title":"Nucl. Acids Res."},{"key":"87998_CR23","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1093\/nar\/gkg595","volume":"31","author":"M Zuker","year":"2003","unstructured":"Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucl. Acids Res. 31, 3406\u20133415. https:\/\/doi.org\/10.1093\/nar\/gkg595 (2003).","journal-title":"Nucl. Acids Res."},{"key":"87998_CR24","doi-asserted-by":"publisher","first-page":"a003665","DOI":"10.1101\/cshperspect.a003665","volume":"2","author":"DH Mathews","year":"2010","unstructured":"Mathews, D. H., Moss, W. N. & Turner, D. H. Folding and finding RNA secondary structure. Cold Spring Harbor Perspect. Biol. 2, a003665 (2010).","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"87998_CR25","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41419-019-1870-0","volume":"10","author":"S Engelberg","year":"2019","unstructured":"Engelberg, S., Netzer, E., Assaraf, Y. G. & Livney, Y. D. Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo. Cell Death Dis. 10, 702. https:\/\/doi.org\/10.1038\/s41419-019-1870-0 (2019).","journal-title":"Cell Death Dis."},{"key":"87998_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/0008-5472.CAN-17-2880","volume":"78","author":"Y Wan","year":"2018","unstructured":"Wan, Y. et al. Aptamer-conjugated extracellular nanovesicles for targeted drug delivery. Cancer Res. 78, 798\u2013808. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2880 (2018).","journal-title":"Cancer Res."},{"key":"87998_CR27","doi-asserted-by":"publisher","first-page":"15416","DOI":"10.1073\/pnas.2136683100","volume":"100","author":"DA Daniels","year":"2003","unstructured":"Daniels, D. A., Chen, H., Hicke, B. J., Swiderek, K. M. & Gold, L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc. Natl. Acad. Sci. 100, 15416\u201315421. https:\/\/doi.org\/10.1073\/pnas.2136683100 (2003).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"87998_CR28","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1002\/ar.22990","volume":"297","author":"W Li","year":"2014","unstructured":"Li, W., Chen, H., Yu, M. & Fang, J. Targeted delivery of doxorubicin using a colorectal cancer-specific ssDNA aptamer. Anat. Rec. 297, 2280\u20132288. https:\/\/doi.org\/10.1002\/ar.22990 (2014).","journal-title":"Anat. Rec."},{"key":"87998_CR29","doi-asserted-by":"publisher","unstructured":"Maxfield, F. R. & W\u00fcstner D. Analysis of cholesterol trafficking with fluorescent probes. In Methods in Cell Biology 367\u2013393 (Academic Press Inc., 2012). https:\/\/doi.org\/10.1016\/B978-0-12-386487-1.00017-1.","DOI":"10.1016\/B978-0-12-386487-1.00017-1"},{"key":"87998_CR30","doi-asserted-by":"publisher","first-page":"e33434","DOI":"10.1371\/journal.pone.0033434","volume":"7","author":"L Meng","year":"2012","unstructured":"Meng, L. et al. Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS ONE 7, e33434. https:\/\/doi.org\/10.1371\/journal.pone.0033434 (2012).","journal-title":"PLoS ONE"},{"key":"87998_CR31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1021\/ac701962v","volume":"80","author":"D Shangguan","year":"2008","unstructured":"Shangguan, D. et al. Identification of liver cancer-specific aptamers using whole live cells. Anal. Chem. 80, 721\u2013728. https:\/\/doi.org\/10.1021\/ac701962v (2008).","journal-title":"Anal. Chem."},{"key":"87998_CR32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","volume":"10","author":"RM Neve","year":"2006","unstructured":"Neve, R. M. et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515\u2013527. https:\/\/doi.org\/10.1016\/j.ccr.2006.10.008 (2006).","journal-title":"Cancer Cell"},{"key":"87998_CR33","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767. https:\/\/doi.org\/10.1172\/JCI45014 (2011).","journal-title":"J. Clin. Invest."},{"key":"87998_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1517\/13543770903042337","volume":"19","author":"S Missailidis","year":"2009","unstructured":"Missailidis, S. & Hardy, A. Aptamers as inhibitors of target proteins. Expert Opin. Ther. Pat. 19, 1073\u20131082 (2009).","journal-title":"Expert Opin. Ther. Pat."},{"key":"87998_CR35","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/molecules23040830","volume":"23","author":"M Kim","year":"2018","unstructured":"Kim, M., Kim, D.-M., Kim, K.-S., Jung, W. & Kim, D.-E. Applications of cancer cell-specific aptamers in targeted delivery of anticancer therapeutic agents. Molecules 23, 830 (2018).","journal-title":"Molecules"},{"key":"87998_CR36","doi-asserted-by":"publisher","first-page":"e31970","DOI":"10.1371\/journal.pone.0031970","volume":"7","author":"Y Hu","year":"2012","unstructured":"Hu, Y. et al. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS ONE 7, e31970. https:\/\/doi.org\/10.1371\/journal.pone.0031970 (2012).","journal-title":"PLoS ONE"},{"key":"87998_CR37","doi-asserted-by":"publisher","first-page":"18836","DOI":"10.1038\/s41598-019-55280-x","volume":"9","author":"H Wang","year":"2019","unstructured":"Wang, H. et al. Characterization of a bifunctional synthetic RNA aptamer and a truncated form for ability to inhibit growth of non-small cell lung cancer. Sci. Rep. 9, 18836 (2019).","journal-title":"Sci. Rep."},{"key":"87998_CR38","doi-asserted-by":"publisher","first-page":"7179","DOI":"10.1038\/s41598-017-05840-w","volume":"7","author":"G Wang","year":"2017","unstructured":"Wang, G. et al. Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX. Sci. Rep. 7, 7179. https:\/\/doi.org\/10.1038\/s41598-017-05840-w (2017).","journal-title":"Sci. Rep."},{"key":"87998_CR39","doi-asserted-by":"publisher","first-page":"36436","DOI":"10.18632\/oncotarget.9262","volume":"7","author":"M Duan","year":"2016","unstructured":"Duan, M. et al. Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging. Oncotarget 7, 36436\u201336446. https:\/\/doi.org\/10.18632\/oncotarget.9262 (2016).","journal-title":"Oncotarget"},{"key":"87998_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules15010001","volume":"15","author":"M Avci-Adali","year":"2009","unstructured":"Avci-Adali, M., Paul, A., Wilhelm, N., Ziemer, G. & Wendel, H. P. Upgrading SELEX technology by using lambda exonuclease digestion for single-stranded DNA generation. Molecules 15, 1\u201311. https:\/\/doi.org\/10.3390\/molecules15010001 (2009).","journal-title":"Molecules"},{"key":"87998_CR41","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1038\/s41598-019-40562-1","volume":"9","author":"D Ferreira","year":"2019","unstructured":"Ferreira, D. et al. Rational identification of a colorectal cancer targeting peptide through phage display. Sci. Rep. 9, 3958. https:\/\/doi.org\/10.1038\/s41598-019-40562-1 (2019).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87998-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87998-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87998-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T06:57:28Z","timestamp":1670050648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-87998-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["87998"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-87998-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"30 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8614"}}